Deriglidole NEW
| Price | $276 | $636 | $852 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-16 |
Product Details
| Product Name: Deriglidole | CAS No.: 122830-14-2 |
| Purity: 99.03% | Supply Ability: 10g |
| Release date: 2026/05/16 |
Product Introduction
Bioactivity
| Name | Deriglidole |
| Description | Deriglidole (SL 86-0715) is a peripheral adrenergic receptor antagonist that is a selective inhibitor of alpha2 receptors. Deriglidole inhibits colistin and Idazoxan but does not show activity against prazosin and rat cortical and human platelet α2-adrenergic receptors. |
| In vitro | Deriglidole is a specific inhibitor of α2-receptors. Deriglidole inhibits the binding of [3H] clonidine and [3H] imidazole x, while showing no inhibitory effect on the binding of [3H] prazosin to rat cortex and human platelet α2-adrenergic receptors. Furthermore, it demonstrates greater effectiveness than idazolide in selectively targeting peripheral receptors.[1] |
| In vivo | In mouse pancreatic beta-cells that both deriglidole and SL86.0714 inhibit ATP-sensitive K+ channel with similar potency whereas alpha2-adrenoceptors are blocked only by deriglidole. In diabetic rats, SL84.0418 and deriglidole (10 mg/kg i.p.) fully normalized glucose tolerance whereas SL86.0714 and tolbutamide only slightly improved it. Five min after deriglidole administration in mice a marked and short lasting rise in insulin levels was observed, followed by a progressive reduction of glycemia.[2] |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 32.5 mg/mL (127.27 mM), Sonication is recommended. |
| Keywords | α2 receptor | Deriglidole | AdrenergicReceptor | Adrenergic Receptor |
| Inhibitors Related | Trifluoperazine dihydrochloride | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Buflomedil hydrochloride | Dexmedetomidine hydrochloride | Isoprenaline hydrochloride | D-Mannitol | Mianserin hydrochloride | Trazodone hydrochloride | Atenolol | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Endocrinology-Hormone Compound Library | Anti-Cardiovascular Disease Compound Library | Bioactive Compounds Library Max | Adrenergic Receptor-Targeted Compound Library | GPCR Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
-
CAS:6983-79-5
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $276.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY